{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:02:51Z","timestamp":1794366171265,"version":"4.9.0"},"publisher-location":"Boston, MA","reference-count":192,"publisher":"Springer US","isbn-type":[{"value":"9780387980935","type":"print"},{"value":"9780387980942","type":"electronic"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009]]},"DOI":"10.1007\/978-0-387-98094-2_10","type":"book-chapter","created":{"date-parts":[[2009,9,11]],"date-time":"2009-09-11T14:33:18Z","timestamp":1252679598000},"page":"203-226","source":"Crossref","is-referenced-by-count":39,"title":["Activated Epidermal Growth Factor Receptor in Ovarian Cancer"],"prefix":"10.1007","author":[{"given":"Laurie G.","family":"Hudson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reema","family":"Zeineldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina","family":"Silberberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Sharon","family":"Stack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,6,26]]},"reference":[{"issue":"Suppl 1","key":"10_CR1","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1677\/erc.1.01032","volume":"12","author":"LA Bazley","year":"2005","unstructured":"Bazley LA, Gullick WJ. The epidermal growth factor receptor family. Endocr Relat Cancer. 2005 Jul;12(Suppl 1):S17\u2013S27.","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"10_CR2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.tcb.2006.10.008","volume":"16","author":"B Linggi","year":"2006","unstructured":"Linggi B, Carpenter G. ErbB receptors: new insights on mechanisms and biology. Trends Cell Biol. 2006 Dec;16(12):649\u2013656.","journal-title":"Trends Cell Biol"},{"issue":"7","key":"10_CR3","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrm1962","volume":"7","author":"A Citri","year":"2006","unstructured":"Citri A, Yarden Y. EGF-ERBB signaling: towards the systems level. Nat Rev Mol Cell Biol. 2006 Jul;7(7):505\u2013516.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"10","key":"10_CR4","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1007\/s00018-008-7440-8","volume":"65","author":"MJ Wieduwilt","year":"2008","unstructured":"Wieduwilt MJ, Moasser MM. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci. 2008 May;65(10):1566\u20131584.","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"10_CR5","first-page":"232","volume":"1785","author":"JM Lafky","year":"2008","unstructured":"Lafky JM, Wilken JA, Baron AT, Maihle NJ. Clinical implications of the ErbB\/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta. 2008 Apr;1785(2):232\u2013265.","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"10_CR6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","volume":"5","author":"NE Hynes","year":"2005","unstructured":"Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005 May;5(5):341\u2013354. Review. Erratum in: Nat Rev Cancer. 2005 Jul;5(7):580.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10_CR7","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1053\/j.seminoncol.2006.04.003","volume":"33","author":"J Mendelsohn","year":"2006","unstructured":"Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol. 2006 Aug;33(4):369\u2013385.","journal-title":"Semin Oncol"},{"issue":"1","key":"10_CR8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.gene.2005.10.018","volume":"366","author":"N Normanno","year":"2006","unstructured":"Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006 Jan 17;366(1):2\u201316.","journal-title":"Gene"},{"issue":"9","key":"10_CR9","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1432-0436.2007.00238.x","volume":"75","author":"M Sibilia","year":"2007","unstructured":"Sibilia M, Kroismayr R, Lichtenberger BM, et al. The epidermal growth factor receptor: from development to tumorigenesis. Differentiation. 2007 Nov;75(9):770\u2013787.","journal-title":"Differentiation"},{"issue":"1","key":"10_CR10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2353\/ajpath.2008.070942","volume":"173","author":"MR Schneider","year":"2008","unstructured":"Schneider MR, Werner S, Paus R, Wolf E. Beyond wavy hairs: the epidermal growth factor receptor and its ligands in skin biology and pathology. Am J Pathol. 2008 Jul;173(1):14\u201324.","journal-title":"Am J Pathol"},{"issue":"1","key":"10_CR11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0014-4827(02)00105-2","volume":"284","author":"RC Harris","year":"2003","unstructured":"Harris RC, Chung E, Coffey RJ. EGF receptor ligands. Exp Cell Res. 2003 Mar 10;284(1):2\u201313.","journal-title":"Exp Cell Res"},{"issue":"10","key":"10_CR12","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.cellsig.2005.03.026","volume":"17","author":"AB Singh","year":"2005","unstructured":"Singh AB, Harris RC. Autocrine, paracrine and juxtacrine signaling by EGFR ligands. Cell Signal. 2005 Oct;17(10):1183\u20131193.","journal-title":"Cell Signal"},{"key":"10_CR13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/msb4100195","volume":"3","author":"I Amit","year":"2007","unstructured":"Amit I, Wides R, Yarden Y. Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy. Mol Syst Biol. 2007;3:151.","journal-title":"Mol Syst Biol"},{"issue":"5951","key":"10_CR14","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/307521a0","volume":"307","author":"J Downward","year":"1984","unstructured":"Downward J, Yarden Y, Mayes E, et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature. 1984 Feb 9\u201315;307(5951):521\u2013527.","journal-title":"Nature"},{"issue":"8","key":"10_CR15","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1172\/JCI32278","volume":"117","author":"H Zhang","year":"2007","unstructured":"Zhang H, Berezov A, Wang Q, et al. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest. 2007 Aug;117(8):2051\u20132058.","journal-title":"J Clin Invest"},{"issue":"2","key":"10_CR16","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ceb.2007.02.008","volume":"19","author":"EM Bublil","year":"2007","unstructured":"Bublil EM, Yarden Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol. 2007 Apr;19(2):124\u2013134.","journal-title":"Curr Opin Cell Biol"},{"issue":"29","key":"10_CR17","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.2174\/092986706779026174","volume":"13","author":"JB Johnston","year":"2006","unstructured":"Johnston JB, Navaratnam S, Pitz MW, et al. Targeting the EGFR pathway for cancer therapy. Curr Med Chem. 2006;13(29):3483\u20133492.","journal-title":"Curr Med Chem"},{"issue":"11","key":"10_CR18","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","volume":"358","author":"F Ciardiello","year":"2008","unstructured":"Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008 Mar 13;358(11):1160\u20131174.","journal-title":"N Engl J Med"},{"issue":"10","key":"10_CR19","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.cellsig.2007.06.023","volume":"19","author":"R Zandi","year":"2007","unstructured":"Zandi R, Larsen AB, Andersen P, et al. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal. 2007 Oct;19(10):2013\u20132023.","journal-title":"Cell Signal"},{"issue":"6","key":"10_CR20","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/bies.20582","volume":"29","author":"D Riese","year":"2007","unstructured":"Riese D, Gallo R, Settleman J. Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis. Bioessays. 2007 Jun;29(6):558\u2013565.","journal-title":"Bioessays"},{"issue":"1","key":"10_CR21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 Jan 7;100(1):57\u201370.","journal-title":"Cell"},{"key":"10_CR22","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1146\/annurev.cellbio.21.122303.120306","volume":"21","author":"J Condeelis","year":"2005","unstructured":"Condeelis J, Singer RH, Segall JE. The great escape: when cancer cells hijack the genes for chemotaxis and motility. Annu Rev Cell Dev Biol. 2005;21:695\u2013718.","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"2","key":"10_CR23","first-page":"255","volume":"22","author":"N Auersperg","year":"2001","unstructured":"Auersperg N, Wong AS, Choi KC, et al. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev. 2001 Apr;22(2):255\u2013288.","journal-title":"Endocr Rev"},{"issue":"4","key":"10_CR24","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1210\/me.2005-0185","volume":"20","author":"M Conti","year":"2006","unstructured":"Conti M, Hsieh M, Park JY, et al. Role of the epidermal growth factor network in ovarian follicles. Mol Endocrinol. 2006 Apr;20(4):715\u2013723.","journal-title":"Mol Endocrinol"},{"issue":"7","key":"10_CR25","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/molehr\/gal045","volume":"12","author":"I Ben-Ami","year":"2006","unstructured":"Ben-Ami I, Freimann S, Armon L, et al. Novel function of ovarian growth factors: combined studies by DNA microarray, biochemical and physiological approaches. Mol Hum Reprod. 2006 Jul;12(7):413\u2013419.","journal-title":"Mol Hum Reprod"},{"issue":"4","key":"10_CR26","first-page":"297","volume":"55","author":"KC Choi","year":"2003","unstructured":"Choi KC, Auersperg N. The ovarian surface epithelium: simple source of a complex disease. Minerva Ginecol. 2003 Aug;55(4):297\u2013314.","journal-title":"Minerva Ginecol"},{"issue":"13","key":"10_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399407000324","volume":"9","author":"H Naora","year":"2007","unstructured":"Naora H. The heterogeneity of epithelial ovarian cancers: reconciling old and new paradigms. Expert Rev Mol Med. 2007 May 4;9(13):1\u201312.","journal-title":"Expert Rev Mol Med"},{"key":"10_CR28","first-page":"161","volume":"107","author":"AS Wong","year":"2002","unstructured":"Wong AS, Auersperg N. Normal ovarian surface epithelium. Cancer Treat Res. 2002;107:161\u2013183.","journal-title":"Cancer Treat Res"},{"issue":"8","key":"10_CR29","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00109-006-0054-4","volume":"84","author":"H Lassus","year":"2006","unstructured":"Lassus H, Sihto H, Leminen A, et al. Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med. 2006 Aug;84(8):671\u2013681.","journal-title":"J Mol Med"},{"issue":"4","key":"10_CR30","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/modpathol.3800575","volume":"19","author":"S Stadlmann","year":"2006","unstructured":"Stadlmann S, Gueth U, Reiser U, et al. Epithelial growth factor receptor status in primary and recurrent ovarian cancer. Mod Pathol. 2006 Apr;19(4):607\u2013610.","journal-title":"Mod Pathol"},{"issue":"1","key":"10_CR31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1525-1438.2006.00286.x","volume":"16","author":"I Dimova","year":"2006","unstructured":"Dimova I, Zaharieva B, Raitcheva S, et al. Tissue microarray analysis of EGFR and erbB2 copy number changes in ovarian tumors. Int J Gynecol Cancer. 2006 Jan\u2013Feb;16(1):145\u2013151.","journal-title":"Int J Gynecol Cancer"},{"key":"10_CR32","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1006\/gyno.1997.4764","volume":"66","author":"JV Ilekis","year":"1997","unstructured":"Ilekis JV, Connor JP, Prins GS, et al. Expression of epidermal growth factor and androgen receptors in ovarian cancer. Gynecol Oncol. 1997;66:250\u2013254.","journal-title":"Gynecol Oncol"},{"key":"10_CR33","first-page":"4469","volume":"19","author":"M Baekelandt","year":"1999","unstructured":"Baekelandt M, Kristensen GB, Trope CG, et al. Epidermal growth factor receptor expression has no independent prognostic significance in advanced ovarian cancer. Anticancer Res. 1999;19:4469\u20134474.","journal-title":"Anticancer Res"},{"key":"10_CR34","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1046\/j.1525-1438.2001.011002119.x","volume":"11","author":"I Skirnisdottir","year":"2001","unstructured":"Skirnisdottir I, Sorbe B, Seidal T. The growth factor receptors HER-2\/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma. Int J Gynecol Cancer. 2001;11:119\u2013129.","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"10_CR35","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1002\/jcb.21591","volume":"103","author":"NV Marozkina","year":"2008","unstructured":"Marozkina NV, Stiefel SM, Frierson HF Jr, et al. MMTV-EGF receptor transgene promotes preneoplastic conversion of multiple steroid hormone-responsive tissues. J Cell Biochem. 2008 Apr 15;103(6):2010\u20132018.","journal-title":"J Cell Biochem"},{"issue":"4","key":"10_CR36","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/00004347-199410000-00008","volume":"13","author":"K Stromberg","year":"1994","unstructured":"Stromberg K, Johnson G, O'Connor D, et al. Frequent immunohistochemical detection of EGF supergene family members in ovarian carcinogenesis. Int J Gynecol Pathol. 1994;13(4):342\u2013347.","journal-title":"Int J Gynecol Pathol"},{"key":"10_CR37","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00004347-199701000-00010","volume":"16","author":"H Niikura","year":"1997","unstructured":"Niikura H, Sasano H, Sato S, et al. Expression of epidermal growth factor-related proteins and epidermal growth factor receptor in common epithelial ovarian tumors. Int J Gynecol Pathol. 1997;16:60\u201368.","journal-title":"Int J Gynecol Pathol"},{"key":"10_CR38","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/0959-8049(94)00361-8","volume":"30A","author":"M Feldkamper","year":"1994","unstructured":"Feldkamper M, Enderle-Schmitt U, Hackenberg R, et al. Urinary excretion of growth factors in patients with ovarian cancer. Eur J Cancer. 1994;30A:1851\u20131858.","journal-title":"Eur J Cancer"},{"key":"10_CR39","first-page":"2119","volume":"14","author":"M Ridderheim","year":"1994","unstructured":"Ridderheim M, Cajander S, Tavelin B, et al. EGF\/TGF-\u03b1 and progesterone in urine of ovarian cancer patients. Anticancer Res. 1994;14:2119\u20132123.","journal-title":"Anticancer Res"},{"key":"10_CR40","first-page":"241","volume":"41","author":"NG Shah","year":"1994","unstructured":"Shah NG, Bhatavdekar JM, Doctor SS, et al. Circulating epidermal growth factor (EGF) and insulin-like growth factor-I (IGF-I) in patients with epithelial ovarian carcinoma. Neoplasma. 1994;41:241\u2013243.","journal-title":"Neoplasma"},{"issue":"13","key":"10_CR41","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1158\/1078-0432.CCR-04-1426","volume":"11","author":"Y Tanaka","year":"2005","unstructured":"Tanaka Y, Miyamoto S, Suzuki SO, et al. Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. Clin Cancer Res. 2005 Jul 1;11(13):4783\u20134792.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10_CR42","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.bbrc.2007.11.015","volume":"365","author":"F Yotsumoto","year":"2008","unstructured":"Yotsumoto F, Yagi H, Suzuki SO, et al. Validation of HB-EGF and amphiregulin as targets for human cancer therapy. Biochem Biophys Res Commun. 2008 Jan 18;365(3):555\u2013561.","journal-title":"Biochem Biophys Res Commun"},{"issue":"16","key":"10_CR43","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1158\/0008-5472.CAN-04-0811","volume":"64","author":"S Miyamoto","year":"2004","unstructured":"Miyamoto S, Hirata M, Yamazaki A, et al. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res. 2004 Aug 15;64(16):5720\u20135727.","journal-title":"Cancer Res"},{"issue":"3","key":"10_CR44","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1023\/A:1008350811639","volume":"11","author":"A Casamassimi","year":"2000","unstructured":"Casamassimi A, De Luca A, Agrawal S, et al. EGF-related antisense oligonucleotides inhibit the proliferation of human ovarian carcinoma cells. Ann Oncol. 2000 Mar;11(3):319\u2013325.","journal-title":"Ann Oncol"},{"issue":"24 Pt 1","key":"10_CR45","doi-asserted-by":"crossref","first-page":"8637","DOI":"10.1158\/1078-0432.CCR-05-1436","volume":"11","author":"A Psyrri","year":"2005","unstructured":"Psyrri A, Kassar M, Yu Z, et al. Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8637\u20138643.","journal-title":"Clin Cancer Res"},{"issue":"Suppl","key":"10_CR46","first-page":"127","volume":"1","author":"APG Crijns","year":"2003","unstructured":"Crijns APG, Boezen HM, Schouten JP, et al. Prognostic factors in ovarian cancer: current evidence and future prospects. The ECCO 12 Educational Book Eur J Cancer. 2003;1(Suppl):127\u2013145.","journal-title":"The ECCO 12 Educational Book Eur J Cancer"},{"issue":"2","key":"10_CR47","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1158\/1055-9965.EPI-04-0423","volume":"14","author":"AT Baron","year":"2005","unstructured":"Baron AT, Boardman CH, Lafky JM, et al. Soluble epidermal growth factor receptor (sEGFR) and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):306\u2013318.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"10_CR48","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2174\/1568009023333926","volume":"2","author":"IA Lorimer","year":"2002","unstructured":"Lorimer IA. Mutant epidermal growth factor receptors as targets for cancer therapy. Curr Cancer Drug Targets. 2002 Jun;2(2):91\u2013102.","journal-title":"Curr Cancer Drug Targets"},{"issue":"12 Suppl","key":"10_CR49","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1586\/14737140.7.12s.S45","volume":"7","author":"AM Sonabend","year":"2007","unstructured":"Sonabend AM, Dana K, Lesniak MS. Targeting epidermal growth factor receptor variant III: a novel strategy for the therapy of malignant glioma. Expert Rev Anticancer Ther. 2007 Dec;7(12 Suppl):S45\u2013S50.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"22","key":"10_CR50","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.4161\/cc.6.22.4922","volume":"6","author":"PH Huang","year":"2007","unstructured":"Huang PH, Cavenee WK, Furnari FB, et al. Uncovering therapeutic targets for glioblastoma: a systems biology approach. Cell Cycle. 2007 Aug;6(22):2750\u20132754.","journal-title":"Cell Cycle"},{"issue":"2","key":"10_CR51","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/sj.bjc.6604471","volume":"99","author":"P Graeff de","year":"2008","unstructured":"de Graeff P, Crijns AP, Ten Hoor KA, et al. The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer. 2008 Jul 22;99(2):341\u2013349.","journal-title":"Br J Cancer"},{"issue":"11","key":"10_CR52","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1158\/1078-0432.CCR-07-4171","volume":"14","author":"KD Steffensen","year":"2008","unstructured":"Steffensen KD, Waldstr\u00f8m M, Olsen DA, et al. Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors. Clin Cancer Res. 2008 Jun 1;14(11):3278\u20133282.","journal-title":"Clin Cancer Res"},{"key":"10_CR53","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1146\/annurev.biophys.37.032807.125829","volume":"37","author":"KM Ferguson","year":"2008","unstructured":"Ferguson KM. Structure-based view of epidermal growth factor receptor regulation. Annu Rev Biophys. 2008;37:353\u2013373.","journal-title":"Annu Rev Biophys"},{"issue":"10","key":"10_CR54","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1200\/JCO.2007.12.1178","volume":"26","author":"A Kumar","year":"2008","unstructured":"Kumar A, Petri ET, Halmos B, et al. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol. 2008 Apr 1;26(10):1742\u20131751.","journal-title":"J Clin Oncol"},{"issue":"7","key":"10_CR55","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/JTO.0b013e31817c6094","volume":"3","author":"T Tsakiridis","year":"2008","unstructured":"Tsakiridis T, Cutz JC, Singh G, et al. Association of phosphorylated epidermal growth factor receptor with survival in patients with locally advanced non-small cell lung cancer treated with radiotherapy. J Thorac Oncol. 2008 Jul;3(7):716\u2013722.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10_CR56","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1136\/jcp.2005.027615","volume":"59","author":"B Sonnweber","year":"2006","unstructured":"Sonnweber B, Dlaska M, Skvortsov S, et al. High predictive value of epidermal growth factor receptor phosphorylation but not of EGFRvIII mutation in resected stage I non-small cell lung cancer (NSCLC). J Clin Pathol. 2006 Mar;59(3):255\u2013259.","journal-title":"J Clin Pathol"},{"issue":"5","key":"10_CR57","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3727\/096504003108748348","volume":"13","author":"T Kanematsu","year":"2003","unstructured":"Kanematsu T, Yano S, Uehara H, et al. Phosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients. Oncol Res. 2003;13(5):289\u2013298.","journal-title":"Oncol Res"},{"issue":"10","key":"10_CR58","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/modpathol.3800427","volume":"18","author":"B Papouchado","year":"2005","unstructured":"Papouchado B, Erickson LA, Rohlinger AL, et al. Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod Pathol. 2005 Oct;18(10):1329\u20131335.","journal-title":"Mod Pathol"},{"issue":"5","key":"10_CR59","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1158\/0008-5472.CAN-05-2994","volume":"66","author":"A Kong","year":"2006","unstructured":"Kong A, Leboucher P, Leek R, et al. Prognostic value of an activation state marker for epidermal growth factor receptor in tissue microarrays of head and neck cancer. Cancer Res. 2006;66(5):2834\u20132843.","journal-title":"Cancer Res"},{"issue":"1","key":"10_CR60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/172460080702200101","volume":"22","author":"L Guo","year":"2007","unstructured":"Guo L, Abraham J, Flynn DC, Castranova V, Shi X, Qian Y. Individualized survival and treatment response predictions for breast cancers using phospho-EGFR, phospho-ER, phospho-HER2\/neu, phospho-IGF-IR\/In,phospho-MAPK, and phospho-p70S6K proteins. Int J Biol Markers. 2007 Jan-Mar;22(1):1\u201311.","journal-title":"Int J Biol Markers"},{"issue":"7","key":"10_CR61","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/cncr.22545","volume":"109","author":"EM Posadas","year":"2007","unstructured":"Posadas EM, Liel MS, Kwitkowski V, et al. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer. 2007 Apr 1;109(7):1323\u20131330.","journal-title":"Cancer"},{"issue":"12","key":"10_CR62","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1158\/0008-5472.CAN-07-5046","volume":"68","author":"KD Cowden Dahl","year":"2008","unstructured":"Cowden Dahl KD, Symowicz J, Ning Y, et al. Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent e-cadherin loss in ovarian carcinoma cells. Cancer Res. 2008 Jun 15;68(12):4606\u20134013.","journal-title":"Cancer Res"},{"issue":"3","key":"10_CR63","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/jcp.1041340305","volume":"134","author":"CH Siemens","year":"1988","unstructured":"Siemens CH, Auersperg N. Serial propagation of human ovarian surface epithelium in tissue culture. J Cell Physiol. 1988 Mar;134(3):347\u2013356.","journal-title":"J Cell Physiol"},{"issue":"2","key":"10_CR64","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1006\/excr.1998.4328","volume":"246","author":"M McClellan","year":"1999","unstructured":"McClellan M, Kievit P, Auersperg N, et al. Regulation of proliferation and apoptosis by epidermal growth factor and protein kinase C in human ovarian surface epithelial cells. Exp Cell Res. 1999 Feb 1;246(2):471\u2013479.","journal-title":"Exp Cell Res"},{"issue":"1","key":"10_CR65","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0006-291X(03)01140-9","volume":"307","author":"A Abdollahi","year":"2003","unstructured":"Abdollahi A, Gruver BN, Patriotis C, et al. Identification of epidermal growth factor-responsive genes in normal rat ovarian surface epithelial cells. Biochem Biophys Res Commun. 2003 Jul 18;307(1):188\u2013197.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10_CR66","first-page":"255","volume":"75","author":"A Berchuck","year":"1990","unstructured":"Berchuck A, Olt GJ, Everitt L, et al. The role of peptide growth factors in epithelial ovarian cancer. Obstet Gynecol. 1990;75(2):255\u2013262.","journal-title":"Obstet Gynecol"},{"issue":"2\u20133","key":"10_CR67","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0959-8049(05)80049-8","volume":"28","author":"AJ Crew","year":"1992","unstructured":"Crew AJ, Langdon SP, Miller EP, et al. Mitogenic effects of epidermal growth factor and transforming growth factor-alpha on EGF-receptor positive human ovarian carcinoma cell lines. Eur J Cancer. 1992;28(2\u20133):337\u2013341.","journal-title":"Eur J Cancer"},{"issue":"2\u20133","key":"10_CR68","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0303-7207(92)90158-3","volume":"83","author":"G Ferrandina","year":"1992","unstructured":"Ferrandina G, Scambia G, Benedetti Panici P, et al. Effects of dexamethasone on the growth and epidermal growth factor receptor expression of the OVCA 433 ovarian cancer cells. Mol Cell Endocrinol. 1992 Feb;83(2\u20133):183\u2013193.","journal-title":"Mol Cell Endocrinol"},{"issue":"2","key":"10_CR69","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/0925-4439(92)90061-Q","volume":"1180","author":"L Zhou","year":"1992","unstructured":"Zhou L, Leung BS. Growth regulation of ovarian cancer cells by epidermal growth factor and transforming growth factors alpha and beta 1. Biochim Biophys Acta. 1992 Dec 10;1180(2):130\u2013136.","journal-title":"Biochim Biophys Acta"},{"issue":"7\u20138","key":"10_CR70","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1038\/sj.bjc.6690175","volume":"79","author":"BJ Simpson","year":"1999","unstructured":"Simpson BJ, Bartlett JM, Macleod KG, et al. Inhibition of transforming growth factor alpha (TGF-alpha)-mediated growth effects in ovarian cancer cell lines by a tyrosine kinase inhibitor ZM 252868. Br J Cancer. 1999 Mar;79(7\u20138):1098\u20131103.","journal-title":"Br J Cancer"},{"issue":"12","key":"10_CR71","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1002\/1097-0142(20011215)92:12<3068::AID-CNCR10149>3.0.CO;2-5","volume":"92","author":"Z Chen","year":"2001","unstructured":"Chen Z, Fadiel A, Feng Y, et al. Ovarian epithelial carcinoma tyrosine phosphorylation, cell proliferation, and ezrin translocation are stimulated by interleukin 1alpha and epidermal growth factor. Cancer. 2001 Dec 15;92(12):3068\u20133075.","journal-title":"Cancer"},{"issue":"3","key":"10_CR72","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/sj.bjc.6600058","volume":"86","author":"JM Sewell","year":"2002","unstructured":"Sewell JM, Macleod KG, Ritchie A, et al. Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 (\u201cIressa\u201d). J Cancer. 2002 Feb 1;86(3):456\u2013462.","journal-title":"J Cancer"},{"key":"10_CR73","first-page":"247","volume":"107","author":"NJ Maihle","year":"2002","unstructured":"Maihle NJ, Baron AT, Barrette BA, et al. EGF\/ErbB receptor family in ovarian cancer. Cancer Treat Res. 2002;107:247\u2013258.","journal-title":"Cancer Treat Res"},{"issue":"4","key":"10_CR74","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/1097-0215(20001115)88:4<566::AID-IJC8>3.0.CO;2-D","volume":"88","author":"O Alper","year":"2000","unstructured":"Alper O, De Santis ML, Stromberg K, et al. Anti-sense suppression of epidermal growth factor receptor expression alters cellular proliferation, cell-adhesion and tumorigenicity in ovarian cancer cells. Int J Cancer. 2000;88(4):566\u2013574.","journal-title":"Int J Cancer"},{"key":"10_CR75","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/jnci\/93.18.1375","volume":"93","author":"O Alper","year":"2007","unstructured":"Alper O, Bergmann-Leitner ES, Bennett TA, et al. Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst. 2007;93:1375\u20131384.","journal-title":"J Natl Cancer Inst"},{"key":"10_CR76","first-page":"1269","volume":"5","author":"KR Brader","year":"1998","unstructured":"Brader KR, Wolf JK, Chakrabarty S, et al. Epidermal growth factor receptor (EGFR) antisense transfection reduces the expression of EGFR and suppresses the malignant phenotype of a human ovarian cancer cell line. Oncol Rep. 1998;5:1269\u20131274.","journal-title":"Oncol Rep"},{"issue":"3","key":"10_CR77","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1158\/0008-5472.CAN-03-1982","volume":"64","author":"SD Pack","year":"2004","unstructured":"Pack SD, Alper OM, Stromberg K, et al. Simultaneous suppression of epidermal growth factor receptor and c-erbB-2 reverses aneuploidy and malignant phenotype of a human ovarian carcinoma cell line. Cancer Res. 2004;64(3):789\u2013794.","journal-title":"Cancer Res"},{"issue":"11","key":"10_CR78","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1002\/1097-0142(19941201)74:11<2984::AID-CNCR2820741115>3.0.CO;2-M","volume":"74","author":"H Kurachi","year":"1994","unstructured":"Kurachi H, Morishige K, Adachi H, et al. Implantation and growth of epidermal growth factor (EGF) receptor expressing human ovarian cancer xenografts in nude mice is dependent on EGF. Cancer. 1994 Dec 1;74(11):2984\u20132990.","journal-title":"Cancer"},{"issue":"7","key":"10_CR79","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S0959-8049(98)00043-4","volume":"34","author":"BC Baguley","year":"1998","unstructured":"Baguley BC, Marshall ES, Holdaway KM, et al. Inhibition of growth of primary human tumour cell cultures by a 4-anilinoquinazoline inhibitor of the epidermal growth factor receptor family of tyrosine kinases. Eur J Cancer. 1998 Jun;34(7):1086\u20131090.","journal-title":"Eur J Cancer"},{"issue":"1 Suppl 1","key":"10_CR80","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1053\/sonc.2003.50028","volume":"30","author":"FM Sirotnak","year":"2003","unstructured":"Sirotnak FM. Studies with ZD1839 in preclinical models. Semin Oncol. 2003 Feb;30(1 Suppl 1):12\u201320.","journal-title":"Semin Oncol"},{"key":"10_CR81","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/sj.bjc.6602315","volume":"92","author":"SJ Park","year":"2005","unstructured":"Park SJ, Armstrong S, Kim Ch, et al. Lack of EGF receptor contributes to drug sensitivity of human germline cells. Br J Cancer. 2005;92:334\u2013341.","journal-title":"Br J Cancer"},{"key":"10_CR82","first-page":"2405","volume":"3","author":"K Wosikowski","year":"1997","unstructured":"Wosikowski K, Schuurhuis D, Kops GJ, et al. Altered gene expression in drug-resistant human breast cancer cells. Clin Cancer Res. 1997;3:2405\u20132414.","journal-title":"Clin Cancer Res"},{"key":"10_CR83","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0303-7207(95)03535-F","volume":"110","author":"BM Dickstein","year":"1995","unstructured":"Dickstein BM, Wosikowski K, Bates SE. Increased resistance to cytotoxic agents in ZR75B human breast cancer cells transfected with epidermal growth factor receptor. Mol Cell Endocrinol. 1995;110:205\u2013211.","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"10_CR84","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1677\/erc.0.0110051","volume":"11","author":"D Melisi","year":"2004","unstructured":"Melisi D, Troiani T, Damiano V, et al. Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments. Endocr Relat Cancer. 2004 Mar;11(1):51\u201368.","journal-title":"Endocr Relat Cancer"},{"issue":"14","key":"10_CR85","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1038\/sj.onc.1209999","volume":"26","author":"F Wang","year":"2007","unstructured":"Wang F, Liu R, Lee SW, et al. Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance. Oncogene. 2007 Mar 29;26(14):2006\u20132016.","journal-title":"Oncogene"},{"key":"10_CR86","doi-asserted-by":"crossref","unstructured":"Peng XH, Karna P, Cao Z, et al. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating surviving gene expression. J Biol Chem. 2006 Sep 8;281(36):25903\u201325914.","DOI":"10.1074\/jbc.M603414200"},{"issue":"6 Suppl 9","key":"10_CR87","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1053\/j.seminoncol.2005.04.028","volume":"32","author":"L Milas","year":"2005","unstructured":"Milas L, Raju U, Liao Z, et al. Targeting molecular determinants of tumor chemo-radioresistance. Semin Oncol. 2005 Dec;32(6 Suppl 9):S78\u2013S81.","journal-title":"Semin Oncol"},{"issue":"2","key":"10_CR88","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10147-006-0663-5","volume":"12","author":"J Thariat","year":"2007","unstructured":"Thariat J, Yildirim G, Mason KA, et al. Combination of radiotherapy with EGFR antagonists for head and neck carcinoma. Int J Clin Oncol. 2007 Apr;12(2):99\u2013110.","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"10_CR89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bjc.6604373","volume":"99","author":"G Milano","year":"2008","unstructured":"Milano G, Spano JP, Leyland-Jones B. EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality. Br J Cancer. 2008 Jul 8;99(1):1\u20135.","journal-title":"Br J Cancer"},{"issue":"1 Suppl 4","key":"10_CR90","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1177\/17246008070221s406","volume":"22","author":"G Tortora","year":"2007","unstructured":"Tortora G, Gelardi T, Ciardiello F, et al. The rationale for the combination of selective EGFR inhibitors with cytotoxic drugs and radiotherapy. Int J Biol Markers. 2007 Jan\u2013Mar;22(1 Suppl 4):S47\u2013S52.","journal-title":"Int J Biol Markers"},{"issue":"3","key":"10_CR91","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/CCO.0b013e3282f9b575","volume":"20","author":"C Tourneau Le","year":"2008","unstructured":"Le Tourneau C, Siu LL. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck. Curr Opin Oncol. 2008 May;20(3):256\u2013263.","journal-title":"Curr Opin Oncol"},{"issue":"8","key":"10_CR92","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1158\/0008-5472.CAN-03-3013","volume":"65","author":"JK Chan","year":"2005","unstructured":"Chan JK, Pham H, You XJ, et al. Suppression of ovarian cancer cell tumorigenicity and evasion of Cisplatin resistance using a truncated epidermal growth factor receptor in a rat model. Cancer Res. 2005 Apr 15;65(8):3243\u20133248.","journal-title":"Cancer Res"},{"issue":"5","key":"10_CR93","first-page":"2053","volume":"6","author":"F Ciardiello","year":"2000","unstructured":"Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res. 2000 May;6(5):2053\u20132063.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10_CR94","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.bcp.2006.07.022","volume":"72","author":"HM Coley","year":"2006","unstructured":"Coley, HM, Shotton CF, Ajose-Adeogun A, et al. Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents. Biochem Pharmacol. 2006 Oct 16;72(8):941\u2013948.","journal-title":"Biochem Pharmacol"},{"issue":"20","key":"10_CR95","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1093\/jnci\/dji314","volume":"97","author":"MG del Carmen","year":"2005","unstructured":"del Carmen MG, Rizvi I, Chang Y, et al. Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo. J Natl Cancer Inst. 2005 Oct 19;97(20):1516\u20131524.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10_CR96","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1172\/JCI114885","volume":"86","author":"RD Christen","year":"1990","unstructured":"Christen RD, Hom DK, Porter DC, et al. Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J Clin Invest. 1990 Nov;86(5):1632\u20131640.","journal-title":"J Clin Invest"},{"issue":"2","key":"10_CR97","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/BF00689635","volume":"13","author":"RD Christen","year":"1994","unstructured":"Christen RD, Isonishi S, Jones JA, et al. Signaling and drug sensitivity. Cancer Metastasis Rev. 1994 Jun;13(2):175\u2013189.","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"10_CR98","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/bjc.1995.382","volume":"72","author":"R Kr\u00f6ning","year":"1995","unstructured":"Kr\u00f6ning R, Jones JA, Hom DK, et al. Enhancement of drug sensitivity of human malignancies by epidermal growth factor. Br J Cancer. 1995 Sep;72(3):615\u2013619.","journal-title":"Br J Cancer"},{"issue":"2","key":"10_CR99","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.canlet.2008.02.062","volume":"266","author":"C Cao","year":"2008","unstructured":"Cao C, Lu S, Sowa A, Kivlin et al. Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs. Cancer Lett. 2008 Aug 8;266(2):249\u2013262.","journal-title":"Cancer Lett"},{"issue":"4","key":"10_CR100","first-page":"909","volume":"5","author":"F Ciardiello","year":"1999","unstructured":"Ciardiello F, Bianco R, Damiano V, et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res. 1999 Apr;5(4):909\u2013916.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10_CR101","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/jnci\/89.5.341","volume":"89","author":"J Mendelsohn","year":"1997","unstructured":"Mendelsohn J, Fan Z. Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst. 1997 Mar 5;89(5):341\u2013343.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10_CR102","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0006-2952(03)00291-0","volume":"66","author":"JM Xu","year":"2003","unstructured":"Xu JM, Azzariti A, Severino M, et al. Characterization of sequence-dependent synergy between ZD1839 (\u201cIressa\u201d) and oxaliplatin. Biochem Pharmacol. 2003 Aug 15;66(4):551\u2013563.","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"10_CR103","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s00280-003-0687-8","volume":"52","author":"JM Xu","year":"2003","unstructured":"Xu JM, Azzariti A, Colucci G, et al. The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines. Cancer Chemother Pharmacol. 2003 Dec;52(6):442\u2013448.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10_CR104","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bcp.2004.03.014","volume":"68","author":"A Azzariti","year":"2004","unstructured":"Azzariti A, Xu JM, Porcelli L, et al. The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839). Biochem Pharmacol. 2004 Jul 1;68(1):135\u2013144.","journal-title":"Biochem Pharmacol"},{"key":"10_CR105","first-page":"111","volume-title":"Rise and Fall of Epithelial Phenotype: Concepts of Epithelial-Mesenchymal Transition","author":"ED Hay","year":"2005","unstructured":"Hay, ED. EMT concept and examples from the vertebrate embryo. In: Savagner P, ed. Rise and Fall of Epithelial Phenotype: Concepts of Epithelial-Mesenchymal Transition. Berlin: Springer; 2005:111\u2013134."},{"key":"10_CR106","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ceb.2005.08.001","volume":"17","author":"MA Huber","year":"2005","unstructured":"Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005;17:548\u2013558.","journal-title":"Curr Opin Cell Biol"},{"key":"10_CR107","first-page":"111","volume-title":"Rise and Fall of Epithelial Phenotype: Concepts of Epithelial-Mesenchymal Transition","author":"VL Marck Van","year":"2005","unstructured":"Van Marck VL, Bracke ME. Epithelial-mesenchymal transitions in human cancer. In: Savagner P, ed. Rise and Fall of Epithelial Phenotype: Concepts of Epithelial-Mesenchymal Transition. Berlin: Springer; 2005:111\u2013134."},{"key":"10_CR108","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/00313020701329914","volume":"39","author":"M Guarino","year":"2007","unstructured":"Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology. 2007;39:305\u2013318.","journal-title":"Pathology"},{"issue":"4","key":"10_CR109","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/jcb.21215","volume":"101","author":"JC Tse","year":"2007","unstructured":"Tse JC, Kalluri R. Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem. 2007;101(4):816\u2013829.","journal-title":"J Cell Biochem"},{"issue":"6","key":"10_CR110","doi-asserted-by":"crossref","first-page":"C1532","DOI":"10.1152\/ajpcell.00478.2005","volume":"290","author":"N Ahmed","year":"2006","unstructured":"Ahmed N, Maines-Bandiera S, Quinn MA, et al. Molecular pathways regulating EGF-induced epithelio-mesenchymal transition in human ovarian surface epithelium. Am J Physiol Cell Physiol. 2006;290(6):C1532\u2013C1542.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"4\u20135","key":"10_CR111","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.drup.2008.07.001","volume":"11","author":"M Sabbah","year":"2008","unstructured":"Sabbah M, Emami S, Redeuilh G, et al. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Dug Resist Updat. 2008;11(4\u20135):123\u2013151.","journal-title":"Dug Resist Updat"},{"issue":"6","key":"10_CR112","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s10585-007-9121-7","volume":"25","author":"S Barr","year":"2008","unstructured":"Barr S, Thomson S, Buck E, et al. Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like ransitions. Clin Exp Metastasis. 2008;25(6):685\u2013693.","journal-title":"Clin Exp Metastasis"},{"issue":"19","key":"10_CR113","doi-asserted-by":"crossref","first-page":"9066","DOI":"10.1158\/0008-5472.CAN-07-0575","volume":"67","author":"HW Lo","year":"2007","unstructured":"Lo HW, Hsu SC, Xia W, et al. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res. 2007 Oct 1;67(19):9066\u20139076.","journal-title":"Cancer Res"},{"issue":"15","key":"10_CR114","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1158\/1078-0432.CCR-08-0234","volume":"14","author":"MY Lee","year":"2008","unstructured":"Lee MY, Chou CY, Tang MJ, et al. Epithelial-mesenchymal transition in cervical cancer: Correlation with tumor progression, epidermal growth factor receptor overexpression, and snail up-regulation. Clin Cancer Res. 2008 Aug 1;14(15):4743\u20134750.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10_CR115","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1038\/sj.onc.1210915","volume":"27","author":"S Uttamsingh","year":"2008","unstructured":"Uttamsingh S, Bao X, Nguyen KT, et al. Synergistic effect between EGF and TGF-beta1 in inducing oncogenic properties of intestinal epithelial cells. Oncogene. 2008 Apr 17;27(18):2626\u20132634.","journal-title":"Oncogene"},{"key":"10_CR116","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/0-387-28671-3_8","volume-title":"Rise and Fall of Epithelial Phenotype: Concepts of Epithelial-Mesenchymal Transition","author":"V Arnoux","year":"2005","unstructured":"Arnoux V, C\u00f4me C, Hudson, LG et al. Cutaneous wound reepithelialization: A partial and reversible EMT. In: Savagner P, ed. Rise and Fall of Epithelial Phenotype: Concepts of Epithelial-Mesenchymal Transition. Berlin: Springer, 2005:111\u2013134."},{"issue":"3","key":"10_CR117","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/(SICI)1097-0215(19981029)78:3<331::AID-IJC13>3.0.CO;2-9","volume":"78","author":"SM Ellerbroek","year":"1998","unstructured":"Ellerbroek SM, Hudson LG, Stack MS. Proteinase requirements of epidermal growth factor-induced ovarian cancer cell invasion. Int J Cancer. 1998 Oct 29;78(3):331\u2013337.","journal-title":"Int J Cancer"},{"issue":"20","key":"10_CR118","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-05-0407","volume":"65","author":"Y Ning","year":"2005","unstructured":"Ning Y, Zeineldin R, Liu Y, et al. Down-regulation of integrin alpha2 surface expression by mutant epidermal growth factor receptor (EGFRvIII) induces aberrant cell spreading and focal adhesion formation. Cancer Res. 2005 Oct 15;65(20):9280\u20139286.","journal-title":"Cancer Res"},{"issue":"5","key":"10_CR119","first-page":"1855","volume":"61","author":"SM Ellerbroek","year":"2001","unstructured":"Ellerbroek SM, Halbleib JM, Benavidez M, et al. Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res. 2001 Mar 1;61(5):1855\u20131861.","journal-title":"Cancer Res"},{"issue":"7","key":"10_CR120","first-page":"2448","volume":"8","author":"M Fujimura","year":"2002","unstructured":"Fujimura M, Hidaka T, Saito S. Selective inhibition of the epidermal growth factor receptor by ZD1839 decreases the growth and invasion of ovarian clear cell adenocarcinoma cells. Clin Cancer Res. 2002 Jul;8(7):2448\u20132454.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10_CR121","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.yexcr.2004.11.007","volume":"304","author":"JM Sewell","year":"2005","unstructured":"Sewell JM, Smyth JF, Langdon SP. Role of TGF alpha stimulation of the ERK, PI3 kinase and PLC gamma pathways in ovarian cancer growth and migration. Exp Cell Res. 2005 Mar 10;304(1):305\u2013316.","journal-title":"Exp Cell Res"},{"issue":"4","key":"10_CR122","first-page":"1003","volume":"29","author":"L Qiu","year":"2006","unstructured":"Qiu L, Zhou C, Sun Y, Di W, et al. Crosstalk between EGFR and TrkB enhances ovarian cancer cell migration and proliferation. Int J Oncol. 2006 Oct;29(4):1003\u20131011.","journal-title":"Int J Oncol"},{"issue":"1","key":"10_CR123","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ygyno.2005.09.038","volume":"101","author":"E Henic","year":"2006","unstructured":"Henic E, Sixt M, Hansson S, et al. EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor. Gynecol Oncol. 2006 Apr;101(1):28\u201339.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10_CR124","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1158\/1541-7786.MCR-07-0019","volume":"5","author":"KD Cowden Dahl","year":"2007","unstructured":"Cowden Dahl KD, Zeineldin R, Hudson LG. PEA3 is necessary for optimal epidermal growth factor receptor-stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells. Mol Cancer Res. 2007 May;5(5):413\u2013421.","journal-title":"Mol Cancer Res"},{"issue":"11","key":"10_CR125","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/mc.20237","volume":"45","author":"R Zeineldin","year":"2006","unstructured":"Zeineldin R, Rosenberg M, Ortega D, et al. Mesenchymal transformation in epithelial ovarian tumor cells expressing epidermal growth factor receptor variant III. Mol Carcinog. 2006 Nov;45(11):851\u2013860.","journal-title":"Mol Carcinog"},{"issue":"13","key":"10_CR126","doi-asserted-by":"crossref","first-page":"6351","DOI":"10.1158\/0008-5472.CAN-07-0883","volume":"67","author":"L Rosan\u00f2","year":"2007","unstructured":"Rosan\u00f2 L, Di Castro V, Spinella F, et al. Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity. Cancer Res. 2007 Jul 1;67(13):6351\u20136359.","journal-title":"Cancer Res"},{"issue":"12","key":"10_CR127","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1158\/1541-7786.MCR-07-0060","volume":"5","author":"O Rosso","year":"2007","unstructured":"Rosso O, Piazza T, Bongarzone I, et al. The ALCAM shedding by the metalloprotease ADAM17\/TACE is involved in motility of ovarian carcinoma cells. Mol Cancer Res. 2007 Dec;5(12):1246\u20131253.","journal-title":"Mol Cancer Res"},{"issue":"11","key":"10_CR128","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1210\/en.2007-0361","volume":"148","author":"HY Zhou","year":"2007","unstructured":"Zhou HY, Pon YL, Wong AS. Synergistic effects of epidermal growth factor and hepatocyte growth factor on human ovarian cancer cell invasion and migration: role of extracellular signal-regulated kinase 1\/2 and p38 mitogen-activated protein kinase. Endocrinology. 2007 Nov;148(11):5195\u20135208.","journal-title":"Endocrinology"},{"issue":"2","key":"10_CR129","first-page":"449","volume":"14","author":"H Matsuzaki","year":"2005","unstructured":"Matsuzaki H, Kobayashi H, Yagyu T, et al. Reduced syndecan-1 expression stimulates heparin-binding growth factor-mediated invasion in ovarian cancer cells in a urokinase independent mechanism. Oncol Rep. 2005 Aug;14(2):449\u2013457.","journal-title":"Oncol Rep"},{"issue":"3","key":"10_CR130","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000010160","volume":"48","author":"M Ueda","year":"1999","unstructured":"Ueda M, Ueki M, Terai Y, et al. Biological implications of growth factors on the mechanism of invasion in gynecological tumor cells. Gynecol Obstet Invest. 1999;48(3):221\u2013228.","journal-title":"Gynecol Obstet Invest"},{"issue":"1","key":"10_CR131","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1210\/endo-125-1-126","volume":"125","author":"AB Galway","year":"1989","unstructured":"Galway AB, Oikawa M, Ny T, et al. Epidermal growth factor stimulates tissue plasminogen activator activity and messenger ribonucleic acid levels in cultured rat granulosa cells: mediation by pathways independent of protein kinases-A and -C. Endocrinology. 1989 Jul;125(1):126\u2013135.","journal-title":"Endocrinology"},{"key":"10_CR132","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ceb.2007.02.007","volume":"19","author":"R Fodde","year":"2007","unstructured":"Fodde R, Brabletz T. Wnt\/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol. 2007;19:150\u2013158.","journal-title":"Curr Opin Cell Biol"},{"issue":"6","key":"10_CR133","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10585-008-9171-5","volume":"25","author":"LG Hudson","year":"2008","unstructured":"Hudson LG, Zeineldin R, Stack MS. Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Clin Exp Metastasis. 2008;25(6):643\u2013655.","journal-title":"Clin Exp Metastasis"},{"key":"10_CR134","first-page":"26","volume-title":"The Peritoneum","author":"KE diZerega GSRodgers","year":"1992","unstructured":"diZerega GS and Rodgers KE. Peritoneal Exudate. The Peritoneum, Berlin: Springer Verlag; 1992:26\u201356."},{"issue":"1","key":"10_CR135","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1006\/gyno.2002.6800","volume":"87","author":"J Shen-Gunther","year":"2002","unstructured":"Shen-Gunther J, Mannel RS. Ascites as a predictor of ovarian malignancy. Gynecol Oncol. 2002 Oct;87(1):77\u201383.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10_CR136","doi-asserted-by":"crossref","first-page":"e2425","DOI":"10.1371\/journal.pone.0002425","volume":"3","author":"VM Fa\u00e7a","year":"2008","unstructured":"Fa\u00e7a VM, Ventura AP, Fitzgibbon MP, et al. Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains. PLoS ONE. 2008 Jun 18;3(6):e2425.","journal-title":"PLoS ONE"},{"issue":"6A","key":"10_CR137","first-page":"3713","volume":"27","author":"S Miyamoto","year":"2007","unstructured":"Miyamoto S, Yagi H, Yotsumoto F, et al. New approach to cancer therapy: heparin binding-epidermal growth factor-like growth factor as a novel targeting molecule. Anticancer Res. 2007 Nov\u2013Dec;27(6A):3713\u20133721.","journal-title":"Anticancer Res"},{"key":"10_CR138","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/978-0-387-68969-2_23","volume":"622","author":"S Miyamoto","year":"2008","unstructured":"Miyamoto S, Yagi H, Yotsumoto F, et al. Heparin-binding epidermal growth factor-like growth factor as a new target molecule for cancer therapy. Adv Exp Med Biol. 2008;622:281\u2013295.","journal-title":"Adv Exp Med Biol"},{"issue":"13","key":"10_CR139","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1158\/1078-0432.CCR-05-0973","volume":"11","author":"AH Braun","year":"2005","unstructured":"Braun AH, Coffey RJ. Lysophosphatidic acid, a disintegrin and metalloprotease-17 and heparin-binding epidermal growth factor-like growth factor in ovarian cancer: the first word, not the last. Clin Cancer Res. 2005 Jul 1;11(13):4639\u20134643.","journal-title":"Clin Cancer Res"},{"issue":"6764","key":"10_CR140","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/47260","volume":"402","author":"N Prenzel","year":"1999","unstructured":"Prenzel N, Zwick E, Daub H, et al. EGF receptor transactivation by G-protein-coupled receptors requires etalloproteinase cleavage of proHB-EGF. Nature. 1999 Dec 23\u201330;402(6764):884\u2013888.","journal-title":"Nature"},{"issue":"7","key":"10_CR141","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.tem.2005.07.005","volume":"16","author":"M Hsieh","year":"2005","unstructured":"Hsieh M, Conti M. G-protein-coupled receptor signaling and the EGF network in endocrine systems. Trends Endocrinol Metab. 2005 Sep;16(7):320\u2013326.","journal-title":"Trends Endocrinol Metab"},{"key":"10_CR142","first-page":"85","volume":"327","author":"OM Fischer","year":"2006","unstructured":"Fischer OM, Hart S, Ullrich A. Dissecting the epidermal growth factor receptor signal transactivation pathway. Methods Mol Biol. 2006;327:85\u201397.","journal-title":"Methods Mol Biol"},{"key":"10_CR143","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2741\/2805","volume":"13","author":"NE Bhola","year":"2008","unstructured":"Bhola NE, Grandis JR. Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Front Biosci. 2008 Jan 1;13:1857\u20131865.","journal-title":"Front Biosci"},{"issue":"1","key":"10_CR144","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1586\/14737140.6.1.73","volume":"6","author":"E Herrmann","year":"2006","unstructured":"Herrmann E, B\u00f6gemann M, Bierer S, et al. The endothelin axis in urologic tumors: mechanisms of tumor biology and therapeutic implications. Expert Rev Anticancer Ther. 2006 Jan;6(1):73\u201381.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"8","key":"10_CR145","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1080\/07357900701522588","volume":"25","author":"M Lalich","year":"2007","unstructured":"Lalich M, McNeel DG, Wilding G, et al. Endothelin receptor antagonists in cancer therapy. Cancer Invest. 2007 Dec;25(8):785\u2013794.","journal-title":"Cancer Invest"},{"issue":"8","key":"10_CR146","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.biocel.2008.01.022","volume":"40","author":"A Bagnato","year":"2008","unstructured":"Bagnato A, Rosan\u00f2 L. The endothelin axis in cancer. Int J Biochem Cell Biol. 2008;40(8):1443\u20131451.","journal-title":"Int J Biochem Cell Biol"},{"issue":"10","key":"10_CR147","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.tem.2007.09.002","volume":"18","author":"R Meidan","year":"2007","unstructured":"Meidan R, Levy N. The ovarian endothelin network: an evolving story. Trends Endocrinol Metab. 2007 Dec;18(10):379\u2013385.","journal-title":"Trends Endocrinol Metab"},{"key":"10_CR148","first-page":"1","volume":"59","author":"A Bagnato","year":"1999","unstructured":"Bagnato A, Salani D, Di Castro V, et al. Expression of endothelin-1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res. 1999;59:1\u20138.","journal-title":"Cancer Res"},{"key":"10_CR149","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0002-9440(10)64791-8","volume":"157","author":"D Salani","year":"2000","unstructured":"Salani D, Di Castro V, Nicotra MR, et al. Role of endothelin-1 in neovascularization of ovarian carcinoma. Am J Pathol. 2000;157:1537\u20131547.","journal-title":"Am J Pathol"},{"key":"10_CR150","first-page":"1306","volume":"57","author":"A Bagnato","year":"1997","unstructured":"Bagnato A, Tecce R, Di Castro V, et al. Activation of mitogenic signaling by endothelin-1 in ovarian carcinoma cells. Cancer Res. 1997;57:1306\u20131311.","journal-title":"Cancer Res"},{"issue":"22","key":"10_CR151","first-page":"8340","volume":"61","author":"L Rosan\u00f2","year":"2001","unstructured":"Rosan\u00f2 L, Varmi M, Salani D, et al. Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res. 2001 Nov 15;61(22):8340\u20138346.","journal-title":"Cancer Res"},{"issue":"6","key":"10_CR152","first-page":"1128","volume":"231","author":"L Rosan\u00f2","year":"2006","unstructured":"Rosan\u00f2 L, Spinella F, Di Castro V, et al. Endothelin-1 is required during epithelial to mesenchymal transition in ovarian cancer progression. Exp Biol Med (Maywood). 2006 Jun;231(6):1128\u20131131.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"6","key":"10_CR153","first-page":"1132","volume":"231","author":"L Rosan\u00f2","year":"2006","unstructured":"Rosan\u00f2 L, Di Castro V, Spinella F, et al. ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation. Exp Biol Med (Maywood). 2006 Jun;231(6):1132\u20131135.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"Suppl 1","key":"10_CR154","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.1097\/01.fjc.0000166255.12229.0d","volume":"44","author":"F Spinella","year":"2004","unstructured":"Spinella F, Rosan\u00f2 L, Elia G, et al. Endothelin-1 stimulates cyclooxygenase-2 expression in ovarian cancer cells through multiple signaling pathways: evidence for involvement of transactivation of the epidermal growth factor receptor. J Cardiovasc Pharmacol. 2004 Nov;44(Suppl 1):S140\u2013S143.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"18","key":"10_CR155","first-page":"5310","volume":"60","author":"F Vacca","year":"2000","unstructured":"Vacca F, Bagnato A, Catt KJ, et al. Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res. 2000 Sep 15;60(18):5310\u20135317.","journal-title":"Cancer Res"},{"key":"10_CR156","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1749-6632.2000.tb06550.x","volume":"905","author":"X Fang","year":"2000","unstructured":"Fang X, Gaudette D, Furui T, et al. Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Ann NY Acad Sci. 2000 Apr;905:188\u2013208.","journal-title":"Ann NY Acad Sci"},{"issue":"11","key":"10_CR157","first-page":"3704","volume":"5","author":"TB Pustilnik","year":"1999","unstructured":"Pustilnik TB, Estrella V, Wiener JR, et al. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin Cancer Res. 1999;5(11):3704\u20133710.","journal-title":"Clin Cancer Res"},{"key":"10_CR158","first-page":"3194","volume":"61","author":"DA Fishman","year":"2001","unstructured":"Fishman DA, Liu Y, Ellerbroek SM, et al. Lysophosphatidic acid promotes matrix metalloproteinase processing and MMP-dependent invasion in ovarian carcinoma cells. Cancer Res. 2001;61:3194\u20133199.","journal-title":"Cancer Res"},{"issue":"5","key":"10_CR159","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1158\/0008-5472.CAN-06-2808","volume":"67","author":"J Symowicz","year":"2007","unstructured":"Symowicz J, Adley BP, Woo MMM, et al. Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells. Cancer Res. 2007;67(5):2030\u20132039.","journal-title":"Cancer Res"},{"key":"10_CR160","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1158\/0008-5472.CAN-04-0060","volume":"12","author":"D Bian","year":"2004","unstructured":"Bian D, Su S, Mahanivong C, et al. Lysophosphatidic acid stimulates ovarian cancer cell migration via a ras-MEK kinase 1 pathway. Cancer Res. 2004;12:4209\u20134217.","journal-title":"Cancer Res"},{"issue":"46","key":"10_CR161","doi-asserted-by":"crossref","first-page":"32835","DOI":"10.1074\/jbc.274.46.32835","volume":"274","author":"M Laffargue","year":"1999","unstructured":"Laffargue M, Raynal P, Yart A, et al. An 3-kinase by lysophosphatidic acid. J Biol Chem 1999; 274(46):32835\u201332841.","journal-title":"J Biol Chem"},{"issue":"3","key":"10_CR162","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/(SICI)1097-4644(20000301)76:3<386::AID-JCB6>3.0.CO;2-9","volume":"76","author":"SN Kim","year":"2000","unstructured":"Kim SN, Park JG, Lee EB, et al. Characterization of epidermal growth factor receptor function in lysophosphatidic acid signaling in PC12 cells. J Cell Biochem. 2000;76(3):386\u2013393.","journal-title":"J Cell Biochem"},{"key":"10_CR163","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/978-1-4757-3587-1_16","volume-title":"Cancer treatment and research: Ovarian cancer","author":"S Ghosh","year":"2002","unstructured":"Ghosh S, Wu Y, Stack MS. Ovarian cancer-associated proteinases. In Stack MS, Fishman DA, editors. Cancer treatment and research: Ovarian cancer. Boston: Kluwer Academic Press; 2002:331\u2013352."},{"issue":"5","key":"10_CR164","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1158\/0008-5472.CAN-06-2808","volume":"67","author":"J Symowicz","year":"2007","unstructured":"Symowicz J, Adley BP, Gleason KJ, et al. Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Res. 2007 Mar 1;67(5):2030\u20132039.","journal-title":"Cancer Res"},{"issue":"2","key":"10_CR165","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1158\/1541-7786.MCR-06-0319","volume":"5","author":"TV Do","year":"2007","unstructured":"Do TV, Symowicz JC, Berman DM, et al. Lysophosphatidic acid down-regulates stress fibers and up-regulates pro-matrix metalloproteinase-2 activation in ovarian cancer cells. Mol Cancer Res. 2007 Feb;5(2):121\u2013131.","journal-title":"Mol Cancer Res"},{"key":"10_CR166","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1476-4598-5-69","volume":"5","author":"KE Fisher","year":"2006","unstructured":"Fisher KE, Pop A, Koh W, et al. Tumor cell invasion of collagen matrices requires coordinate lipid agonist-induced G-protein and membrane-type matrix metalloproteinase-1-dependent signaling. Mol Cancer. 2006 Dec 8;5:69.","journal-title":"Mol Cancer"},{"issue":"11","key":"10_CR167","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1158\/1541-7786.MCR-06-0153","volume":"4","author":"FQ Wang","year":"2006","unstructured":"Wang FQ, Smicun Y, Calluzzo N, et al. Inhibition of matrilysin expression by antisense or RNA interference decreases lysophosphatidic acid-induced epithelial ovarian cancer invasion. Mol Cancer Res. 2006 Nov;4(11):831\u2013841.","journal-title":"Mol Cancer Res"},{"issue":"2","key":"10_CR168","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ygyno.2004.08.001","volume":"95","author":"J So","year":"2004","unstructured":"So J, Navari J, Wang FQ, et al. Lysophosphatidic acid enhances epithelial ovarian carcinoma invasion through the increased expression of interleukin-8. Gynecol Oncol. 2004 Nov;95(2):314\u2013322.","journal-title":"Gynecol Oncol"},{"key":"10_CR169","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1006\/gyno.2000.5806","volume":"77","author":"LW Huang","year":"2000","unstructured":"Huang LW, Garrett AP, Bell DA, et al. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors. Gynecol Oncol. 2000;77:369\u2013376.","journal-title":"Gynecol Oncol"},{"key":"10_CR170","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1023\/A:1006723011835","volume":"17","author":"B Davidson","year":"1999","unstructured":"Davidson B, Goldberg I, Gotlieb WH, et al. High levels of MMP2, MMP9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis 1999;17:799\u2013808.","journal-title":"Clin Exp Metastasis"},{"key":"10_CR171","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/ijc.2910580110","volume":"58","author":"MS Naylor","year":"1994","unstructured":"Naylor MS, Stamp GW, Davies BD, et al. Expression and activity of MMPs and their regulators in ovarian cancer. Int J Cancer. 1994;58:50\u201356.","journal-title":"Int J Cancer"},{"key":"10_CR172","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8<1457::AID-CNCR13>3.0.CO;2-4","volume":"80","author":"DA Fishman","year":"1997","unstructured":"Fishman DA, Bafetti LM, Banionis S, et al. Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells. Cancer. 1997;80:1457\u20131463.","journal-title":"Cancer"},{"key":"10_CR173","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/gyno.1996.0195","volume":"62","author":"TN Young","year":"1996","unstructured":"Young TN, Rodriguez GC, Rindhart AR, et al. Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. Gynecol Oncol. 1996;62:89\u201399.","journal-title":"Gynecol Oncol"},{"key":"10_CR174","first-page":"150","volume":"16","author":"DA Fishman","year":"1996","unstructured":"Fishman, DA, Bafetti, LM, Stack MS. Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells. Invasion Metastasis. 1996;16:150\u2013159.","journal-title":"Invasion Metastasis"},{"key":"10_CR175","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0959-8049(00)00094-0","volume":"36","author":"YA DeClerck","year":"2000","unstructured":"DeClerck YA. Interactions between tumour cells and stromal cells and proteolytic modification of the extracellular matrix by metalloproteinases in cancer. Eur J Cancer. 2000;36:1258\u20131268.","journal-title":"Eur J Cancer"},{"issue":"8","key":"10_CR176","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s10585-007-9104-8","volume":"24","author":"O Wever De","year":"2007","unstructured":"De Wever O, Derycke L, Hendrix A, et al. Soluble cadherins as cancer biomarkers. Clin Exp Metastasis. 2007;24(8):685\u2013697.","journal-title":"Clin Exp Metastasis"},{"key":"10_CR177","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/ijc.2910580315","volume":"58","author":"AL Veatch","year":"1994","unstructured":"Veatch AL, Carson LF, Ramakrishnan S. Differential expression of the cell-cell adhesion molecule E cadherin in ascites and solid human ovarian tumor cells. Int J Can. 1994;58:393\u2013399.","journal-title":"Int J Can"},{"key":"10_CR178","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1093\/humrep\/13.10.2831","volume":"13","author":"E Darai","year":"1997","unstructured":"Darai E, Bringuier AF, Walker-Combrouze F, et al. Soluble adhesion molecules in serum and cyst fluid from patients with cystic tumors of the ovary. Human Repord. 1997;13:2831\u20132835.","journal-title":"Human Repord"},{"key":"10_CR179","first-page":"65","volume":"21","author":"K Sundfeldt","year":"2001","unstructured":"Sundfeldt K, Ivarsson K, Rask K, et al. Higher levels of soluble E-cadherin in cyst fluid from malignant ovarian tumors than in benign cysts. Anticancer Res. 2001;21:65\u201370.","journal-title":"Anticancer Res"},{"issue":"6","key":"10_CR180","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1535-6108(03)00304-0","volume":"4","author":"Z Lu","year":"2003","unstructured":"Lu Z, Ghosh S, Wang Z, Hunter T. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell. 2003;4(6):499\u2013515.","journal-title":"Cancer Cell"},{"issue":"4","key":"10_CR181","first-page":"789","volume":"16","author":"WP Tsang","year":"2006","unstructured":"Tsang WP, Kong SK, Kwok TT. Epidermal growth factor induction of resistance to topoisomerase II toxins in human squamous carcinoma A431 cells. Oncol Rep. 2006;16(4):789\u2013793.","journal-title":"Oncol Rep"},{"issue":"19","key":"10_CR182","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1038\/sj.onc.1210071","volume":"26","author":"A Sharif","year":"2007","unstructured":"Sharif A, Legendre P, Pr\u00e9vot V, et al. Transforming growth factor alpha promotes sequential conversion of mature astrocytes into neural progenitors and stem cells. Oncogene. 2007 Apr 26;26(19):2695\u20132706.","journal-title":"Oncogene"},{"issue":"10","key":"10_CR183","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.1073\/pnas.95.10.5724","volume":"95","author":"M Nagane","year":"1998","unstructured":"Nagane M, Levitzki A, Gazit A, et al. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci USA. 1998 May 12;95(10):5724\u20135729.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10_CR184","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.radonc.2007.04.025","volume":"83","author":"SA Weppler","year":"2007","unstructured":"Weppler SA, Li Y, Dubois L, et al. Expression of EGFR variant vIII promotes both radiation resistance and hypoxia tolerance. Radiother Oncol. 2007 Jun;83(3):333\u2013339.","journal-title":"Radiother Oncol"},{"issue":"36","key":"10_CR185","doi-asserted-by":"crossref","first-page":"6095","DOI":"10.1038\/sj.onc.1207870","volume":"23","author":"RB Luwor","year":"2004","unstructured":"Luwor RB, Zhu HJ, Walker F, et al. The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR. Oncogene. 2004 Aug 12; 23(36):6095\u20136104.","journal-title":"Oncogene"},{"issue":"2","key":"10_CR186","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/jcb.20554","volume":"96","author":"MW Pedersen","year":"2005","unstructured":"Pedersen MW, Pedersen N, Damstrup L, et al. Analysis of the epidermal growth factor receptor specific transcriptome: effect of receptor expression level and an activating mutation. J Cell Biochem. 2005 Oct 1;96(2):412\u2013427.","journal-title":"J Cell Biochem"},{"issue":"5","key":"10_CR187","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ijc.11566","volume":"108","author":"MW Pedersen","year":"2004","unstructured":"Pedersen MW, Tkach V, Pedersen N, Berezin V, Poulsen HS. Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility. Int J Cancer. 2004 Feb 20;108(5):643\u2013653.","journal-title":"Int J Cancer"},{"issue":"12","key":"10_CR188","first-page":"3335","volume":"62","author":"A Lal","year":"2002","unstructured":"Lal A, Glazer CA, Martinson HM, et al. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res. 2002 Jun 15; 62(12):3335\u20133339.","journal-title":"Cancer Res"},{"issue":"1","key":"10_CR189","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/ijc.1572","volume":"97","author":"L Damstrup","year":"2002","unstructured":"Damstrup L, Wandahl Pedersen M, Bastholm L, Elling F, Skovgaard Poulsen H. Epidermal growth factor receptor mutation type III transfected into a small cell lung cancer cell line is predominantly localized at the cell surface and enhances the malignant phenotype. Int J Cancer. 2002 Jan 1;97(1):7\u201314.","journal-title":"Int J Cancer"},{"issue":"9","key":"10_CR190","doi-asserted-by":"crossref","first-page":"6380","DOI":"10.1074\/jbc.M610915200","volume":"282","author":"Y Ning","year":"2007","unstructured":"Ning Y, Buranda T, Hudson LG. Activated epidermal growth factor receptor induces integrin alpha2 internalization via caveolae\/raft-dependent endocytic pathway. J Biol Chem. 2007 Mar 2;282(9):6380\u20136387.","journal-title":"J Biol Chem"},{"issue":"7047","key":"10_CR191","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature03688","volume":"436","author":"DC Radisky","year":"2005","unstructured":"Radisky DC, Levy DD, Littlepage LE, et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature. 2005 Jul 7;436(7047):123\u2013127.","journal-title":"Nature"},{"issue":"8","key":"10_CR192","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/sj.onc.1203347","volume":"19","author":"MD Sternlicht","year":"2000","unstructured":"Sternlicht MD, Bissell MJ, Werb Z. The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter. Oncogene. 2000 Feb 21;19(8):1102\u20131113.","journal-title":"Oncogene"}],"container-title":["Cancer Treatment and Research","Ovarian Cancer"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-0-387-98094-2_10.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T17:08:12Z","timestamp":1605632892000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-0-387-98094-2_10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009]]},"ISBN":["9780387980935","9780387980942"],"references-count":192,"URL":"https:\/\/doi.org\/10.1007\/978-0-387-98094-2_10","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-0-387-98094-2","asserted-by":"object"}]},"ISSN":["0927-3042"],"issn-type":[{"value":"0927-3042","type":"print"}],"subject":[],"published":{"date-parts":[[2009]]}}}